SCHEMBL4174362

SCHEMBL4174362

O=C(O)Cn1cc(-c2cccs2)c(=O)[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.49
POLB P06746 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 4/20 0.45
P2RY2 P41231 1/20 0.43
APEX1 P27695 1/20 0.40
TSHR P16473 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ERCC1 P07992 2/20 0.39
FEN1 P39748 2/20 0.39
ERCC4 Q92889 2/20 0.39
ADORA3 P0DMS8 1/20 0.37
PIM1 P11309 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
RECQL P46063 1/20 0.36
DAO P14920 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162994 0.84 KMT2A (0.53) KDM4EPOLBTDP1ALDH1A1P2RY2
SCHEMBL4162503 0.81 HPGD (0.56) KDM4EPOLBALDH1A1P2RY2GAA
SCHEMBL29019844 0.79 ASAH1 (0.48) KDM4EPOLBALDH1A1P2RY2DAO
SCHEMBL2496260 0.77 P2RY2 (0.41) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL2492788 0.76 P2RY2 (0.40) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL4173284 0.75 HPGD (0.43) POLBL3MBTL1ALDH1A1P2RY2TSHR
SCHEMBL4174262 0.73 P2RY2 (0.44) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL4156367 0.73 KDM4E (0.43) KDM4EPOLBL3MBTL1ALDH1A1P2RY2
SCHEMBL4894394 0.70 KDM4E (0.50) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL4167699 0.70 L3MBTL1 (0.44) KDM4EPOLBL3MBTL1FEN1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US claimed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO claimed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN KDM4E 2284/4885POLB 1773/4885TDP1 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.